Recently, we have shown that coexpression of hMet and mutant-b-catenin using sleeping beauty transposon/transposase leads to hepatocellular carcinoma (HCC) in mice that corresponds to around 10% of human HCC. In the current study, we investigate whether Ras activation, which can occur downstream of Met signaling, is sufficient to cause HCC in association with mutant-b-catenin. We also tested therapeutic efficacy of targeting b-catenin in an HCC model. We show that mutant-K-Ras (G12D), which leads to Ras activation, cooperates with b-catenin mutants (S33Y, S45Y) to yield HCC in mice. Affymetrix microarray showed > 90% similarity in gene expression in mutant-K-Ras-b-catenin and Met-b-catenin HCC. KRas-b-catenin tumors showed up-regulation of b-catenin targets like glutamine synthetase (GS), leukocyte cell-derived chemotaxin 2, Regucalcin, and Cyclin-D1 and of K-Ras effectors, including phosphorylated extracellular signal-regulated kinase, phosphorylated protein kinase B, phosphorylated mammalian target of rapamycin, phosphorylated eukaryotic translation initiation factor 4E, phosphorylated 4E-binding protein 1, and p-S6 ribosomal protein. Inclusion of dominant-negative transcription factor 4 at the time of K-Ras-b-catenin injection prevented HCC and downstream b-catenin and Ras signaling. To address whether targeting b-catenin has any benefit postestablishment of HCC, we administered K-Ras-b-catenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate small interfering RNA targeting catenin beta 1 (CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffered saline for multiple cycles. A significant decrease in tumor burden was evident in the CTNNB1-LNP group versus all controls, which was associated with dramatic decreases in b-catenin targets and some K-Ras effectors, leading to reduced tumor cell proliferation and viability. Intriguingly, in relatively few mice, non-GS-positive tumors, which were evident as a small subset of overall tumor burden, were not affected by b-catenin suppression. HCC is the second-most common cause of death from cancer worldwide.
H epatocellular cancer (HCC) is the most common primary tumor of the liver, accounting for 85% of all primary malignant tumors. It remains a major cancer in less-developed regions of the world, where 83% of the estimated 782,000 new cancer cases worldwide occurred in 2012. HCC is the second-most common cause of death from cancer worldwide.
(1) A disturbing trend, however, has surfaced in HCC incidence and mortality more recently. (2) Whereas the incidence and mortality from many cancers is decreasing worldwide, the incidence rates and death rates associated with HCC are increasing in Abbreviations: 4E-BP1, 4E-binding protein 1; AFP, a-fetoprotein; AKT, protein kinase B; CTNNB1, catenin beta 1; dnTCF4, dominant-negative TCF4; DsiRNA, Dicer substrate small interfering RNA; EIF4E, eukaryotic translation initiation factor 4E; ERK, extracellular signal-regulated kinase; FDR, false discovery rate; GS, glutamine synthetase; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; Lect2, leukocyte cell-derived chemotaxin 2; LNP, lipid nanoparticle; LW/BW, liver weight/body ratio; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; mTOR, mammalian target of rapamycin; p-4E-BP1, phosphorylated 4E-BP1; PBS, phosphate-buffered saline; p-EIF4E, phosphorylated EIF4E; p-ERK, phosphorylated ERK; RTK, receptor tyrosine kinase; SB, sleeping beauty; Scr. LNP, scrambled LNP; TCF4, transcription factor 4; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. many parts of the world, including North America, Latin America, and central Europe. (3) In fact, HCC incidence rates have increased by 3.1% per year from 2008 to 2012. HCC incidence rates increased from 2008 to 2012 among non-Hispanic whites, nonHispanic blacks, and American Indian/Alaska Natives, whereas a decrease was evident among non-Hispanic Asians and Pacific Islanders. More worrisome is also the fact that in contrast to the declining death rates in many common cancers, death rates from HCC have increased by 2.8% per year in men and by 3.4% per year in women. These rising trends in both incidence and mortality, and in both men and women, make it particularly important to understand molecular and cellular mechanisms of HCC for improved understanding and therapies, which remain limited currently. The most effective therapy for HCC continues to be surgery, in the form of liver resection or liver transplantation. Sorafenib is the only effective drug for unresectable HCC with some survival benefit. Thus, overall, there is an urgent need to both identify molecular targets and perform preclinical studies in relevant animal models that represent human disease.
Activation of the Ras signaling pathway attributed to several molecular aberrations is evident in significant subsets of HCC cases. (4, 5) Mutations in K-RAS in HCC are rare and reported in around 7% of cases. (6) However, K-ras mutation in p53 null background or in cooperation with isocitrate dehydrogenase 1 leads to cholangiocarcinoma. (7, 8) Activation of Wnt/b-catenin signaling is also well known in HCC. (9) The chief mechanism of this activation is missense mutations in the exon-3 region of b-catenin gene, which render it resistant to ubiquitin-proteosome degradation leading to constitutive activation of the pathway. However, bcatenin activation alone does not induce spontaneous HCC, (10) and only occasionally will cause tumors by itself, for example, if it is expressed in progenitor cells. (11) We have previously shown that expression of hMet, which is the cognate receptor tyrosine kinase (RTK) for hepatocyte growth factor, along with mutant-b-catenin, leads to HCC in mice. (12) Moreover, around 10% of human HCC overexpress hMet and have catenin beta 1 (CTNNB1) mutations simultaneously. In fact, we showed that gene expression profiles from tumors that occurred in hMet-mutant-bcatenin mice were 70% similar to human HCCs, which had Met activation and b-catenin mutations. The tumor-bearing livers in this model showed enhanced expression of both b-catenin targets and Met effectors like extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), Ras, and protein kinase B (AKT)/mammalian target of rapamycin (mTOR).
In the current study, we chose to express mutant-bcatenin (serine 33 to tyrosine or S33Y-b-catenin and S45Y-b-catenin) and mutant K-Ras (G12D) to address cooperative activation of b-catenin and Ras signaling in HCC using sleeping beauty (SB) transposon/transposase and hydyrodynamic tail vein injection. (13) This led to notable HCC in both G12D-KRas-S45Y-b-catenin and G12D-K-Ras-S33Y-bcatenin models, which histologically mimicked tumors in the Met-b-catenin model. (12) Furthermore, gene expression from tumor-bearing livers was almost 100% concordant between the K-Ras-b-catenin and Met-b-catenin model, suggesting Ras activation downstream of hMet signaling to be a major contributor of HCC in cooperation with b-catenin signaling. We show the importance of b-catenin signaling in tumor initiation in the K-Ras-b-catenin model given that introduction of dominant-negative transcription factor 4 (TCF4; dnTCF4), at the time of delivery of K-Ras and bcatenin, completely prevented HCC while impairing phosphorylated ERK (p-ERK) and partially impairing AKT/mTOR signaling. Last, we inhibited b-catenin in the G12D-K-Ras-S45Y-b-catenin model after establishing HCC through use of EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate small interfering RNA (DsiRNA) targeting CTNNB1 (CTNNB1-LNP). Such treatment led to a significant decrease in tumor burden, which was associated with impaired b-catenin signaling, modest decrease in p-ERK and p-mTOR, and decreased cell proliferation and increased cell death. Thus, this study demonstrates the efficacy of b-catenin suppression in a clinically relevant HCC model.
Materials and Methods

CONSTRUCTS AND REAGENTS
The constructs used for mouse injections pT3-EF5a-S33Y-mutant-b-catenin-Myc-Tag, pT3-EF5a-S45Y-mutant-b-catenin-Myc-tag, pT3-EF5a-dnTCF4, and pCMV-SB transposase have been described. (12) The construct, pT3-EF5a-G12D-mutant-K-Ras, was obtained from Dr. Xin Chen (University of California San Francisco, San Francisco, CA) and subcloned into pT3-EF5a plasmid by the Gateway PCR cloning strategy (Invitrogen, Carlsbad, CA). All the plasmids used for the in vivo experiment were purified using the Endotoxin free Maxi prep kit (Sigma-Aldrich, St. Louis, MO).
Additional methods are available in the Supporting Information.
STATISTICAL ANALYSIS
Where applicable all data are presented as mean 6 standard error (SE). Statistical differences among the various groups were assessed with Tukey-Kramer's test and P value < 0.05 was considered statistically significant. All statistics were performed with Prism 6, version 6.0 (GraphPad Software Inc., La Jolla, CA).
Results
CONCOMITANT EXPRESSION OF MUTANT K-Ras AND MUTANT b-CATENIN IN LIVER LEADS TO DEVELOPMENT OF HCC IN MICE
Mutations in K-RAS or activation of RTKs, such as hMet, can lead to stimulation of Ras-Raf-MEK (MAPK kinase)-ERK signaling. Given that hMetmutant-b-catenin coexpression in mice led to HCC that represented around 10% of human HCC, we next asked whether Ras activation downstream of hMet could also cooperate with mutant b-catenin to cause HCC. We delivered by hydrodynamic tail vein injection in around 6-week-old FVB male mice either constitutively active G12D-K-Ras alone (n 5 3), S45Y-bcatenin alone (n 5 11), S33Y-b-catenin alone (n 5 10), G12D-K-Ras-S45Y-b-catenin (n 5 8), or G12D-K-Ras-S33Y-b-catenin (n 5 8). Increased morbidity and mortality attributed to enlarged abdominal girth and excessive hepatic tumor burden was evident in both G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin groups, whereas none of the individual groups showed any compromise in survival (Fig. 1A,B) . Almost the entire livers were filled grossly with tumors at 7 weeks in the G12D-KRas-S45Y-b-catenin group and at 8 weeks in the G12D-K-Ras-S33Y-b-catenin group (Fig. 1C,D) . The tumors in these two groups were histologically indistinguishable and comprised well-differentiated HCCs composed of tumor cells with basophilic cytoplasm, limited nuclear atypia, and mild lipid accumulation, very similar to what was reported for the Metmutant-b-catenin model (Fig. 1C,D) . Areas of normal eosinophil staining hepatocytes were observed compressed in between the tumor nodules. The HCC nodules also stained positive for known HCC markers, such as Glypican-3 and a-fetoprotein (AFP; Fig.  1C,D) .
Given that mutant-b-catenin SB plasmid had a Myc tag, we followed the evolution of tumors in the K-Ras-b-catenin model. At 1 week after tail vein injection, Myc-positive isolated hepatocytes were visible in pericentral regions in both the G12D-K-Ras- S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin groups ( Fig. 2A,B) . Only around 1% of hepatocytes showed Myc positivity at this time. By 2 weeks, focal expansion of Myc-positive hepatocytes to a few cells were evident in the G12D-K-Ras-S45Y-b-catenin group, whereas mostly Myc-positive single hepatocytes were still evident in the G12D-K-Ras-S33Y-bcatenin group. At 3 weeks in the G12D-K-Ras-S45Y-b-catenin group, several islands of Myc-positive hepatocytes were evident whereas only a few isolated clones of Myc-positive cells were visible in the G12D-K-Ras-S33Y-b-catenin group at this time. At 4 weeks in the G12D-K-Ras-S45Y-b-catenin group and at 6 weeks in the G12D-K-Ras-S33Y-b-catenin group, large areas composed of Myc-positive tumor cells were evident throughout liver sections ( Fig. 2A,B ).
HIGH MOLECULAR SIMILARITY BETWEEN K-Ras-b-CATENIN AND hMet-b-CATENIN TUMORS
Given that the tumors in the K-Ras-b-catenin model histologically resembled HCCs that occurred in the previously published hMet-b-catenin model and we hypothesized that Ras activation downstream of hMet may be cooperating with mutant b-catenin in hepatocarcinogenesis, we next performed microarray analysis on RNA isolated from tumor-bearing livers in the KRas-b-catenin model. We first compared gene expression profiles of tumor-bearing livers from G12D-KRas-S45Y-b-catenin and G12D-K-Ras-S33Y-bcatenin mice. The correspondence between fold change in the two models is depicted as a scatter plot (Supporting Fig. S1 ). Changes in both models were qualitatively similar, but there were 82 genes that were significantly different (Q-value false discovery rate [FDR], < 0.2) between the two models (Pearson correlation coefficient 5 0.91; P < 1e-16). There is a general trend toward the G12D-K-Ras-S45Y-b-catenin model producing changes of smaller magnitude. All significantly different genes are marked orange and the top 30 are labeled.
Furthermore, greater than 90% concordance between the gene expression of tumor-bearing livers from G12D-K-Ras-S45Y-b-catenin and G12D-KRas-S33Y-b-catenin mice, and tumor-bearing livers from hMet-S45Y-b-catenin and hMet-S33Y-bcatenin mice, was observed as reflected by a Pearson correlation coefficient of 0.9124766 (P 5 2.2e-16; Fig.  3A ). However, there were 873 genes that were significantly different (Q-value FDR, < 0.2) between the two, though most of these differences were small in magnitude. The genes that were significantly different between the two are marked in orange and the top 50 are labeled (Fig. 3A) .
ACTIVATION OF b-CATENIN, mTOR, AND ERK SIGNALING IS EVIDENT IN K-Ras-b-CATENIN LIVERS
To elucidate the molecular mechanisms mediating tumor development in the K-Ras-b-catenin model, we analyzed the key downstream signaling pathways of both b-catenin and Ras signaling cascades in tumorbearing livers. As compared to age-matched FVB control livers, both G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin livers showed an increase in multiple b-catenin targets by representative Although the changes in G12D-K-Ras-S45Y/S33Y-b-catenin and hMet-S45Y/S33Y-b-catenin livers were very similar, there were 873 genes that were significantly different (Q-value FDR, < 0.2) between the two, though most of these differences were small in magnitude. The correspondence between fold change in the G12D-K-Ras-S45Y/S33Y-b-catenin and hMet-S45Y/S33Y-bcatenin models is depicted in the scatter plot. All genes that were significantly different between the two are marked orange and the top 50 are labeled. (B) Whole-cell lysates from G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin livers showed dramatic increase in the levels of Lect2 and GS, and modest increase in the levels of regucalcin and cyclin-D1, as compared to agematched wild type control (WT) FVB livers. Comparable loading was confirmed by GAPDH. (C) Whole-cell lysates from G12D-KRas-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin livers showed increased levels of P-ERK and comparable levels of ERK, pSer473-AKT, and AKT compared to WT livers. Comparable loading was confirmed by GAPDH. (D) Western analysis of liver whole-cell lysates from G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin mice showed modest increases in levels of p-Ser2448-and p-Ser2481-mTOR, whereas total mTOR remained unchanged. Meanwhile, increased levels of p-4E-BP1 and pSer235/236 ribosomal protein and p-Ser240/244 ribosomal protein were observed in whole-cell lysates from livers of G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin mice as compared to WT controls, whereas both p-EIF4E and EIF4E were comparable. Comparable loading was verified by GAPDH. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WT, wild type. western blots. Whereas modest increases in Regucalcin and cyclin-D1 were observed, dramatic increases were evident in levels of leukocyte cell-derived chemotaxin 2 (Lect2) and glutamine synthetase (GS), which are considered surrogate targets of Wnt signaling in the liver (Fig. 3B) . Next, we examined the status of AKT/mTOR signaling in livers of G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin mice. No changes in total AKT or p-Ser473-AKT were observed when comparing control livers to G12D-K-Ras-S45Y-bcatenin and G12D-K-Ras-S33Y-b-catenin livers (Fig.  3C ). However, a notable increase in p-ERK was observed in K-Ras-b-catenin livers as compared to controls (Fig. 3C) . Despite no changes in AKT, we next looked at mTOR signaling. Whereas total mTOR remained unchanged, a modest increase in pSer2448-and p-Ser2481-mTOR was observed in both G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin livers (Fig. 4D) . Also, no change in phosphorylated EIF4E (p-EIF4E) or total eukaryotic translation initiation factor 4E (EIF4E) were observed but both phosphorylated 4E-BP1 (p-4E-BP1; 4E-binding protein 1) and p-Ser235/236-and p-Ser240/ 244-S6 ribosomal protein were evident in the G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-bcatenin groups as compared to control livers (Fig. 3D) .
Thus, whereas b-catenin and ERK activation was unequivocally evident in K-Ras-b-catenin model, activation of AKT/mTOR was also evident, although with minor discrepancies.
TRANSCRIPTIONALLY ACTIVE b-CATENIN IS ESSENTIAL FOR HEPATOCARCINOGENESIS IN ASSOCIATION WITH K-Ras
As a transcriptional coactivator, b-catenin functions by interacting with a panel of transcription factors, such as the TCF family, to promote gene expression. To determine whether TCF4 is the transcription factor required for K-Ras-b-catenininduced tumors, we codelivered K-Ras-mutant-bcatenin (S45Y or S33Y) along with dnTCF4, which lacks the ability to bind to the promoter of its target genes, to mouse livers through hydrodynamic tail vein injection. Administration of G12D-K-Ras-S45Y-b-catenin-dnTCF4 or G12D-K-Ras-S33Y-b-catenin-dnTCF4 completely prevented tumor development in mice even up to 12 weeks postinjection, by which time 100% mortality was evident in the G12D-K-Ras-S45Y-b-catenin and G12D-KRas-S33Y-b-catenin groups (Fig. 4A) . As expected, G12D-K-Ras-S45Y-b-catenin mice showed enormous tumor burden by 6 weeks, whereas G12D-KRas-S45Y-b-catenin-dnTCF4 mice showed absence of gross or microscopic disease even at 12 weeks (Fig. 4B) . Similarly, by 7 weeks, G12D-K-Ras-S33Y-b-catenin livers showed notable gross and histological evidence of notable tumor burden, whereas G12D-K-Ras-S33Y-b-catenin-dnTCF4 livers were completely devoid of tumors grossly or microscopically even at 12 weeks postinjection (Fig. 4C) .
We next assessed livers from G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S45Y-bcatenin-dnTCF4 mice as well as G12D-K-Ras-S33Y-b-catenin and S33Y-b-catenin-dnTCF4 mice to address molecular changes specifically interrupted by lack of b-catenin-TCF4 activation. A modest decrease in Regucalcin and cyclin-D1 and a dramatic decrease in Lect2 and GS were evident in dnTCF4-injected cohorts in both forms of bcatenin mutants (Fig. 5) . Intriguingly, we were unable to find any differences in either AKT or pSer473-AKT in the presence of dnTCF4. A dramatic decrease in p-ERK in the presence of dnTCF4 suggests a true cooperation between bcatenin and K-Ras in this model of HCC (Fig. 5) . To determine whether mTOR signaling could be impacted despite lack of changes in AKT, we examined mTOR levels, its phosphorylation, and downstream effectors. We observed modest decreases in both total and p-Ser2448-and p-Ser2481-mTOR in G12D-K-Ras-S45Y-b-catenin-dnTCF4 and G12D-K-Ras-S33Y-b-catenin-dnTCF4, as compared to their respective non-TCF4 counterparts (Fig. 5) . Consistent with these observations, a modest decrease in p-EIF4E, p-4E-BP1, p-Ser235/236 S6 ribosomal protein, and p-Ser240/244 S6 ribosomal protein were evident in livers that were dnTCF4 injected (Fig. 5) These observations indicate that the interaction of b-catenin-TCF4 is critical to cooperate with K-Ras in inducing liver tumors in mice, and that disruption of b-catenin-TCF4 activity completely impairs b-catenin and Ras-Raf-MEK-ERK signaling and partially blocks AKT/mTOR activation.
b-CATENIN SUPPRESSION IN ESTABLISHED HCC IS EFFECTIVE IN SIGNIFICANTLY DECREASING TUMOR BURDEN
To determine the efficacy of therapeutically targeting b-catenin in HCC, we next investigated the use of LNPs to enable tumor-selective delivery of a DsiRNA targeting CTNNB1 (CTNNB1-LNP). Tumor-specific uptake of the LNP has been enabled by a specific chemical composition and manufacturing process as described. (14) Given that tumors were identical between the G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin mice, we selected the G12D-K-Ras-S45Y-b-catenin model to investigate the therapeutic effect of b-catenin suppression. Five weeks after hydrodynamic injection of G12D-K-Ras-S45Y-b-catenin, mice were stratified into three groups, which received intravenously either CTNNB1-LNP or scrambled LNP (Scr. LNP) or phosphate-buffered saline (PBS) alone. The intravenous injections were given by tail vein and for three cycles each of three injections given every 24 hours followed by a 4-day rest period as shown in Fig. 6A . Mice were sacrificed 4 days after the end of the first cycle, second cycle, or third cycle. A significant decrease in liver weight/body ratio (LW/BW) as an indicator of tumor burden was evident in the CTNNB1-LNP group at all stages when compared to either the PBS or Scr. LNP groups (Fig. 6B) . This difference was appreciable grossly; as shown in Fig. 6C , there was a lack of overt tumors in the CTNNB1-LNP-treated group for three cycles versus the Scr. LNP treatment for the same duration (Fig.  6C) . To determine the effect of b-catenin suppression on HCCs, we stained livers from animals in the Scr. LNP and CTNNB1-LNP groups after two or three cycles for Myc-tag, given that all tumors in the K-Ras-b-catenin model were Myc-tag positive (Fig.  2) . As shown in representative tiled images, a dramatic decrease in numbers of Myc-tag-positive tumor nodules were evident after both two cycles and three cycles of CTNNB1-LNP as compared to Scr. LNP (Fig. 6D) .
Giiven that GS is a surrogate target of mutant bcatenin, we next compared GS by immunohistochemistry (IHC) in livers from G12D-K-Ras-S45Y-b-catenin mice after one, two, and three cycles of either CTNNB1-LNP or Scr. LNP. A dramatic decrease in GS-positive areas was observed after bcatenin suppression after any and all cycles of CTNNB1-LNP as compared to Scr. LNP (Fig. 7A) . Furthermore, cyclin-D1, which is also regulated by b-catenin in the liver, (15) although its regulation can be promiscuous, was strongly positive in tumor nodules after one, two, or three cycles of Scr. LNP delivery to G12D-K-Ras-S45Y-b-catenin (Fig. 7B) . However, a dramatic decrease in cyclin-D1 staining was evident after one and two cycles of CTNNB1-LNP whereas its staining was more midzonal after three cycles, similar to its normal localization in adult mice (Fig. 7B) . (16) FIG. 5. Molecular changes associated with lack of b-catenin activation in G12D-K-Ras-S45Y-b-catenin-dnTCF4 and G12D-KRas-S33Y-b-catenin-dnTCF4 livers. (A) Whole-cell lysates from G12D-K-Ras-S45Y-b-catenin-dnTCF4 livers showed decreased levels of b-catenin targets, of which Lect2 and GS were decreased dramatically and Regucalcin and cyclin-D1 were decreased modestly as compared to G12D-K-Ras-S45Y-b-catenin-PT3 to become comparable to FVB wild-type (WT) control livers. Also, a dramatic decrease in P-ERK was observed whereas the total ERK was comparable to controls. No changes in levels of both p-Ser473-AKT and total AKT were found in G12D-K-Ras-S45Y-b-catenin-dnTCF4 lysates. Also observed in these livers were modest decreases in total and p-Ser2448-mTOR, p-Ser2481-mTOR, p-EIF4E, p-4E-BP1, p-Ser235/236 S6 ribosomal protein, and p-Ser240/244 S6 ribosomal protein. Comparable loading was confirmed by GAPDH. (B) Whole-cell lysates from G12D-K-Ras-S33Y-b-catenindnTCF4 livers showed decreases in b-catenin targets, p-ERK, total and p-Ser2448-and p-Ser2481-mTOR, p-EIF4E, p-4E-BP1, pSer235/236 S6 ribosomal protein, and p-Ser240/244 S6 ribosomal protein as compared to G12D-K-Ras-S33Y-b-catenin-PT3 controls. No changes in total ERK, p-Ser473-AKT, or total AKT in G12D-K-Ras-S33Y-b-catenin-dnTCF4 lysates as compared to controls. Equal loading was verified by GAPDH. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WT, wild type.
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RARE MICE SHOW INCOMPLETE RESPONSE TO CTNNB1-LNP ATTRIBUTED TO TUMOR HETEROGENEITY AND EXPANSION OF GS-NEGATIVE TUMORS IN K-Ras-b-CATENIN
We next wanted to address whether tumors occurring in the G12D-K-Ras-S45Y-b-catenin mouse model were homogeneous. This was attributed to the fact that the occasional mouse in the CTNNB1-treatment cohort lacked a comparably pronounced response to treatment as the majority of animals as observed by a modest decrease in LW/BW. To address any tumor heterogeneity, we carefully surveyed tumors in G12D-K-Ras-S45Y-bcatenin livers at 6 and 7 weeks for GS positivity. Intriguingly, whereas predominant HCC nodules in this model were strongly GS positive, there were occasional nodules that lacked any GS staining (Supporting Fig. S2A ). These GS-negative nodules ranged from 1% to 5% in frequency over all animals tested. Given that GS in HCC is regulated exclusively by b-catenin, we next examined whether these tumors still were composed of mutant b-catenin that was hydrodynamically delivered and contained an Myc-tag. Serial sections from two representative G12D-K-Ras-S45Y-b-catenin livers showed that all tumor nodules were Myc-tag positive, but a small subset of these mutant-b-catenin-containing tumors were GS negative (Supporting Fig. S2B ). Last, we investigated whether partial resistance to CTNNB1-LNP treatment could be attributed to growth of mutant-b-catenin-positive, non-GS-positive tumors over time; we assessed serial sections for Myc-tag and GS after three cycles of CTNNB1-LNP treatment. As shown in a representative tiled image, remnant disease in one liver lobe was evident in the form of Myc-positive tumor nodules; however, these nodules were almost exclusively GS negative (Supporting Fig.  S2C ). These observations suggest that b-catenin suppression may be effective in GS-positive HCCs.
TUMOR REGRESSION FOLLOWING b-CATENIN SUPPRESSION IS ATTRIBUTABLE TO IMPAIRMENT IN b-CATENIN SIGNALING AND PARTIAL INHIBITION of mTOR SIGNALING
Next, we assessed tumor livers from controls, Scr. LNP-treated, and CTNNB1-LNP-treated G12D-K-Ras-S45Y-b-catenin mice for b-catenin signaling by western blotting analysis. For the latter two groups, we included a sample each from after one cycle, two cycles, and two samples from after three cycles of treatment. A time-dependent decrease in direct b-catenin targets, including GS, Lect2, Regucalcin, and cyclin-D1, was evident along with a decrease in Myc-tagged-b-catenin and a modest impact when examined for total b-catenin levels (Fig. 8A) . It should be noted that the CTNNB1-LNP in its current formulation was engineered to be selectively taken up by the tumor cells, thus not impacting b-catenin in normal hepatocytes and nonparenchymal cells as published elsewhere. (14) We next investigated the impact of mutant-bcatenin suppression in established HCCs for any effect on Ras-Raf-MEK-ERK signaling and AKT-mTOR signaling. Only a modest impact on p-ERK was evident in the CTNNB1-LNP-treated group as compared to Scr. LNP whereas no clear differences were evident in AKT or p-Ser473-AKT, which actually showed an increase after three cycles of b-catenin suppression (Fig. 8A) . Effect on mTOR signaling was modest and somewhat ambiguous after CTNNB1-LNP treatment. Modest decrease in p-Ser2448-and p-Ser2481-mTOR was observed after b-catenin suppression, along with a decrease in p-EIF4E and pSer235/236 S6 ribosomal protein (Fig. 8A) . However, no decrease was observed in p-4E-BP1 or p-Ser240/ 244 S6 ribosomal protein. These observations suggest that the most pronounced effect of b-catenin suppression in established HCC is on b-catenin signaling, while modestly affecting Ras-Raf-MEK-ERK and AKT-mTOR signaling to eventually cause disease regression.
IMPAIRED PROLIFERATION AND ENHANCED CELL DEATH IS EVIDENT FOLLOWING b-CATENIN SUPPRESSION IN HCC
Last, we wanted to determine the biological effect of b-catenin suppression by CTNNB1-LNP on bcatenin signaling, and Ras-Raf-MEK-ERK and AKT-mTOR signaling in G12D-K-Ras-S45Y-bcatenin mice. We assessed livers after three cycles of Scr. LNP and CTNNB1-LNP treatment for Ki-67, a marker of cells in the S phase of the cell cycle. A notable decrease in the number of Ki-67-positive cells was clearly evident in b-catenin-suppressed livers (Fig.  8B ). To address cell death, we used IHC for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and identified a significant increase in numbers of TUNEL-positive cells in the CTNNB1-LNP group versus the Scr. LNP group (P < 0.0001; Fig. 8C ). Thus b-catenin suppression in established HCC impairs cell survival and affects tumor cell proliferation to eventually lead to tumor regression. 
Discussion
Molecular therapies for HCC are lacking. Identification of key molecular aberrations in HCC that can be targeted are hence of high significance. Equally important is to have in vivo models that represent human disease to enable not only mechanistic studies, but also allow therapeutic testing and validation. We previous showed that overexpressing hMet and mutant b-catenin in murine livers, which occurs concomitantly in around 9%-12.5% of HCC cases in two large cohorts, led to HCC that recapitulated human HCC in that subset at a molecular level. In the current study, we show that Ras activation downstream of such RTKs like hMet is sufficient to cooperate with CTNNB1 mutations to induce clinically relevant HCC. Gene expression from tumors in the K-Ras-bcatenin model was identical to the hMet-mutant-bcatenin model. Thus, the K-Ras-b-catenin and hMetmutant-b-catenin models recapitulate around 10% of all HCCs and are relevant models to study biology and therapeutics.
Ras activation is reported in large subsets of HCC cases ranging from 50% to 100% of all cases attributable to multiple mechanisms (reviewed in Delire and Starkel (17) ). However, Ras activation attributable to mutations in KRAS are rare in human HCC, with one study reporting around 7% incidence (17) . We accessed the COSMIC database (v78; released September 5, 2016) , which showed 52 of 1,730 HCC cases with KRas mutations (1.4%). (18) Of these, 17 had G12D mutations whereas an additional 14 had other G12 mutations (G12C, G12V, and G12S). Overall, the G12 site was mutated in 60% of all K-Ras-mutated HCCs. In our current study, activated K-Ras (G12D-K-Ras) expression by itself did not yield HCC, suggesting that it may cooperate with another signaling pathway in tumorigenesis. Indeed N-Ras, another Ras family member, cooperates with molecules like Sphase kinase-associated protein 2 or AKT in promoting HCC in similar SB models. (19, 20) Ras activation was also observed in the hMet-mutant-b-catenin model. (12) In the current study, we observe Ras activation in the G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin groups. Wnt pathway activation is reported in a notable subset of HCC patients albeit attributed to an array of mechanisms (reviewed in Monga (9) ). CTNNB1 mutations are evident in 25%-40% of HCC cases and are one such mechanism. Furthermore, these HCCs are more differentiated, GS positive, with relatively better overall survival. (1, 21) However, expression of mutant-b-catenin alone is insufficient to induce HCC in transgenic models or by SB-induced expression, as also verified in the current study. (10, 12) Although its cooperation with hMet was reported in mice and patients, here we show its cooperation with Ras signaling, which is a downstream effector of hMet. As expected, b-catenin activation was evident in the G12D-K-Ras-S45Y-b-catenin and G12D-K-Ras-S33Y-b-catenin groups, as shown by up-regulation of many Wnt targets.
Suppression of b-catenin in the K-Ras-mutant-bcatenin HCC model led to a notable reduction in tumors. Indeed, b-catenin suppression in the mouse HCC model, which harbors CTNNB1 mutations, showed a complete response to peptide nucleic acid antisense against b-catenin gene. (22) Effect of bcatenin suppression on HCC may be the net result of suppression of several of its target genes, such as Lect2, Regucalcin, cyclin-D1, and GS. Whereas the role of Regucalcin is mostly in vitamin C biosynthesis in murine livers, it role is unclear in human HCC. (23) Lect2 is known to modulate tumor-related inflammatory response and has been suggested as a mechanism of why b-catenin-mutated tumors are less aggressive. (24) We have identified Lect2 to be a secreted For the latter two groups, we included a sample each from after one cycle, two cycles, and two samples from after three cycles of treatment. A complete loss of Myc-tagged-b-catenin and normalization in total b-catenin levels was evident at all times after CTNNB1 treatment. A timedependent decrease in b-catenin targets, including GS, Regucalcin, cyclin-D1, and Lect2, was observed after CTNNB1-LNP treatment. Modest decreases in P-ERK, p-Ser2448-mTOR, p-Ser2481-mTOR, p-4E-BP1, p-Ser235/236 S6 ribosomal protein, and pSer240/244 S6 ribosomal protein and no changes or even increases in p-Ser473-AKT and p-EIF4E were evident. biomarker in HCC with CTNNB1 mutations, especially in mice. (25) Cyclin-D1 is critical for G 1 -to-Sphase transition during the cell cycle and hence its suppression attributed to inhibition of b-catenin is highly relevant as a mechanism of controlling HCC proliferation. (12, 15) Indeed, a decrease in tumor cell proliferation was evident following b-catenin suppression. Last, the role of GS in known tumor metabolism has been recently shown to be of great relevance. Given that tumors depend on aerobic glycolysis, glutamine is shown to be the source of carbons that replenish the tricarboxylic acid cycle. More recently, in the glioblastoma model, it was shown that the source of glutamine was not glutaminolysis, but GS, and this glutamine was a source of purine biosynthesis. (26) Given that CTNNB1-mutated HCCs are strongly GS positive, because GS is a known direct target of Wnt signaling, (27) a significant effect of b-catenin suppression on HCC may be attributed to GS loss and effect on tumor metabolism. Indeed, CTNNB1-mutated tumors are shown to be glutamine addicted, and glutamine depletion impaired growth of liver tumors with CTNNB1 mutations, both in vitro and in vivo. (28, 29) In addition to Wnt targets, b-catenin suppression in the K-Ras-mutant-b-catenin model also led to suppression of several p-ERK and mTOR, which are independently known to play an important role in tumor proliferation and survival. Hence, b-catenin suppression in HCC has broader effects on signaling that impairs tumor cell proliferation and increases tumor cell death.
It was intriguing to note that blockade of b-catenin activation in the mutant K-Ras-b-catenin model led to a profound decrease in ERK activation, and a modest effect on mTOR activation, but no effect on p-AKT. This suggests specific functional cooperation between the two pathways. Blockade of p-ERK by b-catenin suppression demonstrates a clear cooperation between Wnt and Ras signaling pathways in the current HCC model, which was also evident in the hMet-mutant-bcatenin model. (12) Similar effects on p-ERK and mTOR signaling were also observed when b-catenin was suppressed in existing HCCs with an overall impact on tumor cell survival and proliferation. AKT is a well-known regulator of mTOR, downstream of phosphoinositide 3-kinase signaling. (30) However, in our model, decrease in mTOR signaling was independent of any effect on AKT activation, which continued to occur despite b-catenin suppression. This suggests that AKT activation may be an upstream event of bcatenin and/or Ras/Raf/MEK/ERK signaling.
Continued AKT activation following b-catenin suppression could also be attributed to blockade of Ras/ ERK, which can lead to AKT activation. (30) How is mTOR signaling blocked following b-catenin suppression despite AKT activation? It is known that Ras/ ERK signaling can also regulate mTOR activation. (31) Hence, decreased mTOR signaling following bcatenin suppression is likely a consequence of impaired ERK activation.
The use of LNP is an innovative modality to deliver agents for cancer therapeutics. (32) We have recently demonstrated EnCore as an LNP system for delivery of DsiRNA to b-catenin-dependent tumors. (14) EnCore LNPs represent a unique structural class of nanoparticles and are currently in clinical development for tumor delivery of RNA interference triggers. (33) Encore LNPs carrying CTNNB1-targeting DsiRNA delivered pharmacology-relevant intratumoral concentrations of the oligonucleotide, yielding mRNA silencing and antitumor efficacy in multiple mouse models, including cell-line-derived xenografts, orthotopic patient-derived xenografts, disseminated hematological tumors, colorectal cancer liver metastases, experimental lung metastases, and spontaneous liver tumors induced by specific genetic drivers. (14) In fact, using the Krasmutant-b-catenin model, we showed tumor-specific uptake of the Encore LNP, suggesting this modality to be a timely and innovative means for cancer therapeutics.
It was intriguing to note that even in a model such as mutant-K-Ras-b-catenin, which uses a reductionist approach with only two oncogenes being delivered together, there was some tumor heterogeneity. Whereas 100% of tumors contained mutant-b-catenin as shown by Myc-tag-positivity and GS positivity, the occasional Myc-tag-positive tumor nodule was GS negative. The basis of this observation in such a seemingly homogeneous model is unclear, but does demonstrate that even within the CTNNB1-mutated group of tumors, there may be subclasses and that GS may be a relevant biomarker of those tumors that are most vulnerable to b-catenin suppression. It should be noted that b-catenin activation in HCC in patients is already known to be disparate. Whereas one class of b-catenin activation is attributed to CTNNB1 mutations, other classes of HCC show b-catenin activation attributed to TGFb activation, (34) AXIN1 mutations, (35) or other mechanisms. All of these groups cluster differently in terms of prognosis, etiology, and even association with other functional oncogenic aberrations to result in HCC. (21) Thus, even within the CTNNB1-mutated group and in cooperation with only one oncogene, KRas, there appears to be some heterogeneity, which led to differential response to b-catenin suppression therapy. All GS-positive, b-catenin-positive tumors showed notable involution, but GS-negative, b-catenin 1 tumors appeared to be unaffected and a small subset of animals showed remnant disease composed of GSnegative, b-catenin-positive tumors, albeit still significantly less than Scr. LNP-or PBS-treated controls. The molecular basis of this differential response is currently under investigation. Thus, in conclusion, we show that Ras signaling, downstream of RTKs like hMet, cooperates with bcatenin mutations to cause HCC in mice and patients, and that b-catenin suppression by itself is sufficient to profoundly reduce tumor burden in this clinically relevant model. Given that EnCore therapeutic modality is timely and relevant, its use in patients exhibiting GS 1 , b-catenin 1 HCCs, may be highly relevant.
